指南与共识前列腺增生与排尿功能障碍

AUA/SUFU 特发性膀胱过度活动症诊断与治疗指南

The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder.
指南 / 共识 · J Urol · 2024-04-23

该指南由 AUA/SUFU 制定,基于 2013 年 1 月至 2023 年 11 月的系统检索(共纳入 159 项研究),为特发性膀胱过度活动症(OAB)的诊断评估与治疗提供循证推荐。指南共形成 33 条声明,涵盖非侵入性治疗、药物治疗、微创治疗、侵入性治疗、留置导管及良性前列腺增生(BPH)合并 OAB 的管理,强调通过共享决策制定个体化方案。

要点

  • 指南就 OAB 的诊断评估与治疗给出 33 条循证声明。
  • 治疗选项包括非侵入性、药物、微创、侵入性治疗及留置导管。
  • 强调通过共享决策制定个体化治疗方案以最大化症状控制和生活质量。

核心结论

  • 一旦确诊 OAB,临床医生与患者有多种治疗选择,应通过共享决策制定个体化方案,兼顾循证推荐与患者价值观和偏好。

研究设计与样本

  • 采用 OVID 对 MEDLINE、EMBASE 及 Cochrane 图书馆进行电子检索,系统检索 2013 年 1 月至 2023 年 11 月评估 OAB 诊断与治疗的系统综述和原始研究。
  • 纳入与排除标准基于关键问题及感兴趣的人群、干预、对照、结局、时间、研究类型和设置(PICOTS)。
  • 经研究筛选流程后共纳入 159 项研究,用于形成循证推荐声明。

主要发现

  • 该指南共产生 33 条声明,涵盖疑似 OAB 症状患者的评估与诊断。
  • 声明涵盖 OAB 患者的治疗选项,包括非侵入性治疗、药物治疗、微创治疗、侵入性治疗和留置导管。
  • 声明还涵盖 BPH 合并 OAB 患者的管理。

关键数值与推荐

  • 指南共形成 33 条声明,涵盖 OAB 的评估与诊断、治疗选项及 BPH 合并 OAB 的管理。
  • 治疗选项包括非侵入性治疗、药物治疗、微创治疗、侵入性治疗和留置导管。

临床怎么用

  • 确诊 OAB 后,临床医生与患者应通过共享决策,结合循证推荐及患者价值观与偏好,制定个体化治疗方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this guideline is to provide evidence-based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision-making process, which will maximize symptom control and quality of life, while minimizing adverse events and burden of disease. METHODS: An electronic search employing OVID was used to systematically search the MEDLINE and EMBASE databases, as well as the Cochrane Library, for systematic reviews and primary studies evaluating diagnosis and treatment of OAB from January 2013 to November 2023. Criteria for inclusion and exclusion of studies were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, types of studies and settings (PICOTS) of interest. Following the study selection process, 159 studies were included and were used to inform evidence-based recommendation statements. RESULTS: This guideline produced 33 statements that cover the evaluation and diagnosis of the patient with symptoms suggestive of OAB; the treatment options for patients with OAB, including non-invasive therapies, pharmacotherapy, minimally invasive therapies, invasive therapies, and indwelling catheters; and the management of patients with BPH and OAB. CONCLUSION: Once the diagnosis of OAB is made, the clinician and the patient with OAB have a variety of treatment options to choose from and should, through shared decision-making, formulate a personalized treatment approach taking into account evidence-based recommendations as well as patient values and preferences.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol. 2024. PMID: 38651651. doi:10.1097/JU.0000000000003985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。